Tyrosine kinase inhibitor treatment discontinuation in chronic myeloid leukemia: patient views
| Autor: | Leanne Koningen, Peter E. Westerweel, Jan Jacob Beckeringh, Christel C. L. M. Boons, Vashti N. M. F. Tromp, Jeroen Janssen, Jan de Jong, Jacqueline G. Hugtenburg, Lonneke Timmers, Inge G.P. Geelen |
|---|---|
| Přispěvatelé: | Clinical pharmacology and pharmacy, Hematology, APH - Aging & Later Life, APH - Health Behaviors & Chronic Diseases, CCA - Cancer Treatment and quality of life, APH - Quality of Care |
| Rok vydání: | 2020 |
| Předmět: |
Adult
Oncology Cancer Research medicine.medical_specialty business.industry medicine.drug_class Myeloid leukemia Hematology Disease Tyrosine-kinase inhibitor respiratory tract diseases Discontinuation 03 medical and health sciences Cross-Sectional Studies 0302 clinical medicine Recurrence Leukemia Myelogenous Chronic BCR-ABL Positive 030220 oncology & carcinogenesis Internal medicine Humans Medicine business Protein Kinase Inhibitors 030215 immunology |
| Zdroj: | Leukemia and Lymphoma, 62(3), 649-658. Informa Healthcare Tromp, V N M F, Timmers, L, Koningen, L, Janssen, J J W M, Westerweel, P E, Geelen, I G P, de Jong, J, Beckeringh, J J, Boons, C C L M & Hugtenburg, J G 2021, ' Tyrosine kinase inhibitor treatment discontinuation in chronic myeloid leukemia : patient views ', Leukemia and Lymphoma, vol. 62, no. 3, pp. 649-658 . https://doi.org/10.1080/10428194.2020.1839655 |
| ISSN: | 1029-2403 1042-8194 |
| DOI: | 10.1080/10428194.2020.1839655 |
| Popis: | Patients with chronic myeloid leukemia (CML) in deep molecular remission may discontinue tyrosine kinase inhibitor (TKI) treatment without relapse. The present study aims to gain insight into the views of CML patients on TKI treatment discontinuation and identify factors that are associated with their willingness to discontinue treatment. A cross-sectional study, among adult Dutch CML patients was conducted to assess willingness and their views on benefits of and concerns about discontinuation. A total of 185 patients participated of whom 76% were willing to discontinue TKI-treatment. Patients considered the absence of side effects the most important benefit whereas fear of disease recurrence was their most prominent concern. Adequate monitoring was the most important prerequisite for TKI-treatment discontinuation. However, ambiguity with respect to perquisites indicate that patients on long-term TKI treatment should be adequately informed both on the possibility to discontinue treatment and on its benefits, risks, and measures that address risks. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|